Member Info for Digger01

We should receive the first part of the trail data imminently.
In theory if should be very similar to the DPI. Second half due in Q1 next year.
It’s always been their plan to out license DPI/MDI, so hopefully that won’t be too far away next year if Mdi trials are as successful as the Dpi.
The Nebulused version they will take into Ph3 next year. I also note that only circa 20% of shares are in free float, so IiiiiiiiiF this ever takes off, it will hopefully move quickly. Good luck LTH’s, you know who you are. Over 20% of adult life spent waiting for “significant “ shareholder value.!!!!

A muted response to say the least, which probably reflects the lack of confidence and protracted time lines here. However, a big step forward and expansion of scope. It will be interesting to see how the US responds.

No way will 50% of this business be sold old for £1.50/share.
Lots of key news to come in the six months. Obviously we don’t need any more trial end point misses.
DPI results, nebuliser and midi. FEV is
a primary end point of all of these trials and to the best of my knowledge, most if not all of previous trials, have shown an increase in FEV compared to peers. Like many others, I have been here way too long (10 years) and have around £3 average.
I agree that the PR to the general market is very poor. However, we have a number of big high profile healthcare investors here, who have not flinched. This seems crazy cheap, however, we still await the long promised “significant shareholder value “ good luck all.

We are all lost in the Jungle room for now.
However, we only need one hit record to re-launch.
If this gets to ph3 I have confidence that success will follow. Upcoming Ph2 results critical to repair damage from the last trial which failed to meet the end point.

This is to make you aware that a petition to ban shorting of London AIM stocks has been started.

Consider signing the petition if you agree, - deadline 04.09.2019

https://petition.parliament.uk/petitions/242399

This is to make you aware that a petition to ban shorting of London AIM stocks has been started.

Consider signing the petition if you agree, - deadline 04.09.2019

https://petition.parliament.uk/petitions/242399

Also waiting for part 2 of the current DPI trial, which is trailing a powder formulation looking for end points similar to the Nebulised version which has already proven successful. At least that's my interpretation. If this meets the expected end points then our market is a whole lot bigger.
However, I agree with fellow LT sufferers that this has been a long painful journey with no sign of shareholder value yet. However, I think that the last SP drop based on the last trial as an Add on therapy, was way overdone. Results due this quarter and the start of MDI trial if it's on time. GL

I note that Iron ore price is now over $90. Does anyone have any idea what price would make it profitable for Labrador to re-commence mining?

Hi Rhodi, when do you see us receiving TL data for DPI trial?
The initiating RNS said H2 but the latest conference presentation on the website, seems to suggest Q1.
Any thoughts?

Down nearly 9% but US VRNA up over 3%?

See RNS of 17th Dec.

First half of year.

H1 2019

I agree with bewise, you need to review numerous RNS releases over the last year especially.
Many P2 trials have met the End point which included a 400 patient trial. The purpose of multiple P2 trials is to position the drug and de-risk for P3. The drug has proven success as an add on and stand alone single bronchodilator. The latest trial was as an add on therapy for dual bronchodilators which if successful would have extended the potential market opportunities. We still have $60m + in cash to finalise p2 programme this year. Dead duck - no. However only my opinion as a non medical investor. This went to circa £2 a year ago based on previous trial success, reaction to last RNS, way overdone in my opinion. Time will tell and I eagerly await the results of the latest DPI trial.

Why a buy out?
This lot may well go alone with the Nebulised version in the hospital setting. Any expansion could then be self funding?
If this gets sold, it's going to have to be big bucks, or it would have been sold years ago.
The science has never failed, and previous directors would not sell for peanuts. Unfortunately they did not have enough PH2 proven data to command the price they obviously thought it was worth. The quality and caliber of our main investors put big money in here based on better data gathered and presented by a more savy Bod. There may be further dilution but this is finally getting interesting.

If you read the latest RNS's it would appear that we are now positioning ourselves for PH3. This needs to be very specific for the greatest chance of success. Hopefully all the highly paid Bod and new appointments and 10 years of Ph2 data, hits the target.

That we are still at the same SP as when the POS was $1 lower!

Yes very strange why this keeps dropping with trial results in Jan plus launch of latest.
Anyway, by the end of 2019 we should be into Ph3 if all comes together. I do have confidence that any Ph3 will be successful as it will be targeted and positioned based on all Ph2 data to address the initial market. This seems to be acute COPD in a hospital setting and post maintenance care. We shall see. I hope you all have a great Xmas a prosperous 2019.

What are you referring to and who is AP?
Lucky guess on my part, as it wasn't a secret that the trial was due to start this month.

In saying that, the chances are much better than with this share.